| Literature DB >> 34728679 |
Xiang Ji1, Xia Zhang2, Guojie Li3.
Abstract
To evaluate the changes of left atrial (LA) geometry and function in patients with rheumatoid arthritis (RA) by conventional echocardiography and two-dimensional speckle tracking imaging (2D-STI). We enrolled 46 RA patients with a duration of < 5 years as Group I, 40 RA patients with a duration of ≥ 5 years as Group II, and 40 normal subjects as the control group. Conventional echocardiography was conducted to measure traditional parameters. The LA strain during reservoir phase (LASr), LA strain during conduit phase (LAScd), LA strain during contraction phase (LASct), and LA global longitudinal strain (LAGLS) were obtained from 2D-STI. Related ultrasound results were compared. The LASct was significantly higher in Group I than in control group (P < 0.05). The LASr, LAScd, and LAGLS were significantly lower in Group I than in control group (all P < 0.05). The LASr, LAScd, LASct, and LAGLS were significantly lower in Group II than in control group and Group I (all P < 0.05). The function of LA impaired in RA patients, and the impairment aggravated with the clinical course of RA patients. 2D-STI technology can early and accurately evaluate the LA function of RA patients by evaluating LASr, LAScd, LASct, and LAGLS.Entities:
Mesh:
Year: 2021 PMID: 34728679 PMCID: PMC8563725 DOI: 10.1038/s41598-021-00657-0
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 12D-STI parameters of left atrium in control group. 2D-STI parameters of left atrium obtained from apical four-chamber view in control group (A). 2D-STI parameters of left atrium obtained from apical two-chamber view in control group (B). LAGLS left atrial global longitudinal strain, LASr left atrial strain during reservoir phase, LAScd left atrial strain during conduit phase, LASct left atrial strain during contraction phase, LV left ventricle, LA left atrium, RV right ventricle, RA right atrium.
Figure 22D-STI parameters of left atrium in Group I. 2D-STI parameters of left atrium obtained from apical four-chamber view in Group I (A). 2D-STI parameters of left atrium obtained from apical two-chamber view in Group I (B). LAGLS left atrial global longitudinal strain, LASr left atrial strain during reservoir phase, LAScd left atrial strain during conduit phase, LASct left atrial strain during contraction phase, LV left ventricle, LA left atrium, RV right ventricle, RA right atrium.
Figure 32D-STI parameters of left atrium in Group II. 2D-STI parameters of left atrium obtained from apical four-chamber view in Group II (A). 2D-STI parameters of left atrium obtained from apical two-chamber view in Group II (B). LAGLS left atrial global longitudinal strain, LASr left atrial strain during reservoir phase, LAScd left atrial strain during conduit phase, LASct left atrial strain during contraction phase, LV left ventricle, LA left atrium, RV right ventricle, RA right atrium.
Characteristics of all the subjects.
| Parameter | Control | Group I | Group II | P-value |
|---|---|---|---|---|
| Age (years) | 43.04 ± 6.61 | 44.25 ± 6.69 | 44.61 ± 6.18 | 0.53 |
| BMI (kg/m2) | 21.02 ± 1.96 | 20.78 ± 2.06 | 20.89 ± 1.78 | 0.84 |
| Systolic pressure (mm/Hg) | 115.32 ± 12.27 | 118.64 ± 13.30 | 118.72 ± 13.36 | 0.41 |
| Diastolic pressure (mm/Hg) | 74.35 ± 6.43 | 76.20 ± 6.54 | 77.43 ± 9.39 | 0.19 |
| Female (%) | 75.00 | 78.26 | 72.50 | 0.82 |
| HR (bmp) | 73.92 ± 5.10 | 74.30 ± 5.31 | 73.95 ± 5.31 | 0.93 |
| Smoking (%) | 5.0 | 6.5 | 7.5 | 0.90 |
| Total cholesterol (mg/dL) | 175.6 ± 18.1 | 172.4 ± 20.9 | 177.7 ± 19.8 | 0.46 |
| HDL cholesterol (mg/dL) | 52.0 ± 10.6 | 55.6 ± 11.2 | 55.2 ± 10.8 | 0.27 |
| LDL cholesterol (mg/dL) | 104.6 ± 10.9 | 103.9 ± 11.2 | 105.0 ± 11.7 | 0.89 |
| DMARDs (%) | – | 89.1 | 95.0 | 0.32 |
| NSAIDs (%) | – | 37.0 | 50.0 | 0.22 |
| Corticosteriod (%) | – | 32.6 | 55.0# | 0.04 |
Data are presented as mean ± standard deviation unless otherwise indicated.
BMI body mass index, HR heart rate, HDL cholesterol high density lipoprotein cholesterol; LDL cholesterol low density lipoprotein cholesterol, DMARDs disease modifying anti-rheumatic drugs, NSAIDs nonsteroidal anti-inflammatory drugs.
#Compared with group I, P < 0.05.
Clinical and laboratory parameters.
| Parameter | Control | Group I | Group II | P-value |
|---|---|---|---|---|
| RA duration (years) | – | 2.42 ± 1.13 | 7.21 ± 1.39# | < 0.001 |
| RF positive (%) | – | 66 | 65 | 0.98 |
| RF (IU/ml) | 4.69 (2.87, 7.87) | 138.34 (18.56, 178.61)* | 131.28 (17.32, 183.81)* | < 0.001 |
| Anti CCP positive (%) | – | 62 | 60 | 0.62 |
| Anti CCP (U/ml) | 7.03 (4.70, 9.07) | 180.45 (20.02, 300.31)* | 186.33 (19.93, 296.90)* | < 0.001 |
Data are presented as mean ± standard deviation, median (interquartile range), or positive rate.
RF rheumatoid factor, Anti CCP anti-cyclic peptide containing citrulline.
*Compared with control group, P < 0.05.
#Compared with group I, P < 0.05.
Conventional echocardiographic parameters.
| Parameter | Control | Group I | Group II | P-value |
|---|---|---|---|---|
| LAVImax (ml/m2) | 24.11 ± 2.41 | 30.41 ± 2.82* | 38.56 ± 2.70*# | < 0.001 |
| LAVImin (ml/m2) | 10.13 ± 1.90 | 14.72 ± 1.79* | 24.21 ± 2.99*# | < 0.001 |
| LAVIpre (ml/m2) | 13.31 ± 2.11 | 20.82 ± 2.44* | 29.80 ± 2.90*# | < 0.001 |
| LAEF (%) | 58.18 ± 5.45 | 51.72 ± 3.00* | 37.23 ± 7.05*# | < 0.001 |
| LAPEF (%) | 45.00 ± 5.46 | 31.60 ± 3.96* | 22.68 ± 5.66*# | < 0.001 |
| LAAEF (%) | 25.34 ± 5.93 | 29.46 ± 4.40* | 18.83 ± 4.61*# | < 0.001 |
| E/e | 7.70 ± 1.32 | 12.26 ± 2.06* | 15.56 ± 1.60*# | < 0.001 |
| e | 10.20 ± 1.79 | 7.04 ± 1.15* | 4.82 ± 1.21*# | < 0.001 |
| LVEF (%) | 66.27 ± 2.44 | 65.93 ± 2.16 | 65.56 ± 2.08 | 0.36 |
| LVFS (%) | 36.96 ± 1.31 | 36.65 ± 1.17 | 36.45 ± 1.21 | 0.18 |
| LVMI (g/m2) | 78.68 ± 8.89 | 85.11 ± 13.76* | 97.83 ± 19.03*# | < 0.001 |
| LVPWT (mm) | 8.76 ± 0.21 | 8.82 ± 0.23 | 12.52 ± 0.22*# | < 0.001 |
Data are presented as mean ± standard deviation.
LAVI left atrial maximal volume index, LAVI left atrial minimum volume index, LAVI left atrial presystolic volume index, LAEF left atrial ejection fraction, LAPEF left atrial passive ejection fraction, LAAEF left atrial active ejection fraction, LVEF left ventricular ejection fraction, LVFS left ventricular fractional shortening, LVMI left ventricular mass index, LVPWT left ventricular posterior wall thickness.
*Compared with control group, P < 0.05.
#Compared with group I, P < 0.05.
Strain analysis.
| Parameter | Control | Group I | Group II | P-value |
|---|---|---|---|---|
| LASr (%) | 38.52 ± 3.17 | 28.82 ± 2.17* | 18.42 ± 1.76*# | < 0.001 |
| LAScd (%) | − 22.58 ± 1.91 | − 15.59 ± 1.62* | − 9.46 ± 2.60*# | < 0.001 |
| LASct (%) | − 12.97 ± 1.53 | -15.24 ± 4.70* | − 6.94 ± 1.49*# | < 0.001 |
| LAGLS (%) | 34.56 ± 3.61 | 28.06 ± 2.40* | 17.38 ± 1.34*# | < 0.001 |
Data are presented as mean ± standard deviation.
LASr strain during reservoir phase, LAScd strain during conduit phase, LASct strain during contraction phase, LAGLS left atrial global longitudinal strain.
*Compared with control group, P < 0.05.
#Compared with group I, P < 0.05.
Association between LAGLS and inflammation related indexes in RA patients.
| Variable | Correlation coefficient | P-value |
|---|---|---|
| RF (IU/ml) | − 0.12 | 0.28 |
| Anti CCP (U/ml) | − 0.10 | 0.37 |
RF rheumatoid factor, Anti CCP anti-cyclic peptide containing citrulline.
Association between the clinical course and LA function parameters in RA patients.
| Variable | Correlation coefficient | P-value |
|---|---|---|
| LAGLS (%) | − 0.93 | < 0.001 |
| LASr (%) | − 0.94 | < 0.001 |
| Absolute value of LAScd (%) | − 0.90 | < 0.001 |
| Absolute value of LASct (%) | − 0.73 | < 0.001 |
| LAEF (%) | − 0.93 | < 0.001 |
| LAPEF (%) | − 0.81 | < 0.001 |
| LAAEF (%) | − 0.81 | < 0.001 |
LAGLS left atrial global longitudinal strain, LASr left atrial strain during reservoir phase, LAScd left atrial strain during conduit phase, LASct left atrial strain during contraction phase, LAEF left atrial ejection fraction, LAPEF left atrial passive ejection fraction, LAAEF left atrial active ejection fraction.
Figure 4Linear correlations between LA strain parameters and the parameters of traditional LA function. Linear correlation between LASr and LAEF (A). Linear correlation between absolute value of LAScd and LAPEF (B). Linear correlation between absolute value of LASct and LAAEF (C).
Figure 5Bland–Altman analyses. Bland–Altman analysis of LASr obtained by 2D-STI showed that there was a high consistency in interobservers (A). Bland–Altman analysis of LASr obtained by 2D-STI showed that there was a high consistency in intraobserver (B). Bland–Altman analysis of LAScd obtained by 2D-STI showed that there was a high consistency in interobservers (C). Bland–Altman analysis of LAScd obtained by 2D-STI showed that there was a high consistency in intraobserver (D). Bland–Altman analysis of LASct obtained by 2D-STI showed that there was a high consistency in interobservers (E). Bland–Altman analysis of LASct obtained by 2D-STI showed that there was a high consistency in intraobserver (F).